10,10'-dimethyl-9,9'-biacridinium has been researched along with Disease Exacerbation in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horiuchi, M; Huang, PL; Morishita, T; Nakashima, Y; Sasaguri, Y; Suda, O; Tanimoto, A; Tasaki, H; Tsutsui, M; Yanagihara, N | 1 |
1 other study(ies) available for 10,10'-dimethyl-9,9'-biacridinium and Disease Exacerbation
| Article | Year |
|---|---|
Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice.
Topics: Acridines; Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Blood Pressure; Coronary Artery Disease; Coronary Vessels; Cyclic GMP; Disease Progression; Luminescent Measurements; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microcirculation; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Peptidyl-Dipeptidase A; Time | 2002 |